CDXC

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 104 full-time employees. The company went IPO on 2007-06-25. The firm is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.